Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysisopen access

Authors
손경복
Issue Date
Dec-2020
Publisher
BioMed Central
Keywords
Access to medicines; International agreements; Pricing and reimbursement; Procedural fairness
Citation
Globalization and Health, v.16, no.1, pp 1 - 12
Pages
12
Indexed
SCIE
SSCI
SCOPUS
Journal Title
Globalization and Health
Volume
16
Number
1
Start Page
1
End Page
12
URI
https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/114161
DOI
10.1186/s12992-020-00633-9
ISSN
1744-8603
Abstract
Background: Health systems are struggling with unprecedented drug spending and governments have devised various policy options to manage high-priced medicines. Meanwhile, some pricing and reimbursement processes are currently moving under the jurisdiction of international agreements. This study aims to understand trends in international agreements from the perspectives of pricing and reimbursement policies for newly marketed medicines. Methods: We proposed the framework to interpret the international agreements as code and applied computational text analysis to understand international agreements as data. In particular, we selected the AUSFTA, KORUS, and TPP to assess the progress and evolution in international agreements and investigate the existing relevant content on the pricing and reimbursement of newly marketed medicines. Results: Similar to the provisions for intellectual property, the scope of international agreements regarding pricing and reimbursement decisions are broadened and strengthened. Over time, the domain of transparency, re-naming procedural fairness, has changed significantly more than the remaining domains. Pharmaceutical companies will have more opportunities to advocate for their positions, to protect their interests in decision processes, to investigate the decisions on listings and setting the amounts of reimbursement, and to challenge these decisions. Conclusions: Recently signed international agreements favor companies over governments with underscoring procedural fairness and timely access. However, access to affordable medicines is the goal towards which international agreements should aim. In a similar vein, substantial fairness and the accountability of companies should be discussed when negotiating agreements or adopting international agreements through domestic legislation. © 2020, The Author(s).
Files in This Item
Go to Link
Appears in
Collections
COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Son, Kyung-Bok photo

Son, Kyung-Bok
COLLEGE OF PHARMACY (DEPARTMENT OF PHARMACY)
Read more

Altmetrics

Total Views & Downloads

BROWSE